indication
as of 2026-07-01Intellectual Disability
Competitive landscape
Competitive set
2
2 approved · 0 pipeline
Projection timeline
actual past → guided future · protection walls overlaid
17 events
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
2042
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff
Competitive set
resolved drugs with trials in this indicationdrugUnknown
US-approved 1989 · Clozaril
Phase 21 trial
Protection2028
drugUnknown
US-approved 1996 · ZYPREXA Intramuscular
Phase 21 trial
Protection2041
Market size
prevalence as a range, not a number